1Director, Regulatory Affairs, Amneal Pharmaceuticals of NY LLC, New York, USA
2Director, Regulatory Affairs, Amneal Pharmaceuticals, Piscataway, NJ, USA
3Director, Regulatory Affairs, Zydus Pharmaceuticals USA Inc, Pennington, NJ, USA
*Corresponding author. E-mail address: piyushhmodi@yahoo.in (P. Modi)
Getting first-cycle approval for Abbreviated New Drug Applications (ANDAs) is crucial for generic drug sponsors, especially when quick market entry and regulatory risks are at stake. Even though the U.S. Food and Drug Administration has established clear review processes and goals under the Generic Drug User Fee Amendments (GDUFA), many ANDAs remain delayed by avoidable problems in bioequivalence, chemistry, manufacturing, and controls, labeling, and facility compliance.
This article looks at what affects first-cycle ANDA approval. It highlights the importance of making early regulatory decisions, spotting risks before filing, and keeping the team on the same page. It also covers how to prepare before and after submission, maintain quality, answer review questions, and get ready for inspections.
The article uses performance metrics and real-world examples to show how sponsors can shorten review times and improve their chances of approval. Careful planning and steady execution help organizations avoid last-minute changes and achieve more predictable, timely approvals.
A well-defined and proactive regulatory strategy enhances the prospects of first-cycle ANDA approval. Early identification and mitigation of potential risks, high-quality submission preparation, and effective cross-functional collaboration help minimize review cycles and facilitate more efficient, predictable, and timely regulatory approvals.
ANDA, First-cycle approval, GDUFA, Regulatory planning, Submission quality, Generic drugs, CMC, FDA
